IRMD IRADIMED CORP Insider Trading

CEO Roger E. Susi sold 7,500 shares for $691,043.76 under pre-arranged 10b5-1 plan; retains 2.16M shares

Roger E. Susi executed 4 separate sales totaling 7,500 shares for $691,043.76 at blended average price $92.14 across May 26-27, 2026. As a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, this transaction was scheduled rather than discretionary. The CEO's holdings decreased by only 0.3%, leaving him with 2,165,000 shares post-transaction. At IRMD, Susi's 5 prior sales produced modest positive returns (ranging 3.6% to 6.8% at the 90-day mark), though this historical pattern provides limited predictive value for a pre-scheduled trade. The company shows solid fundamentals with annual revenue growth of 14.4% and net income of $5,818,000, though the stock trades at a P/E of 49.72, well above typical industrial or medical-device peers.

CEO Roger E. Susi sold 7,500 shares for $657,264.82 via scheduled 10b5-1 plan; stock down 2.7% in 30 days, 10.4% in 90 days.

Susi Roger E. executed 6 separate sales totaling 7,500 shares for $657,264.82 across two trading days (May 18–19, 2026), with transaction prices ranging from $85.95 to $88.65 and a blended average of $87.64. This sale reduces his holdings by 0.3% (from 2.18M to 2.17M shares) and is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, making this a scheduled transaction rather than discretionary activity. The current stock price of $90.40 is 16.2% below the 52-week high of $107.90, and the stock has declined 10.4% over the past 90 days and 2.7% over the past 30 days. His prior sales at IRMD have posted positive returns in both 30- and 90-day windows (range: +1.7% to +4.4%), while his cross-ticker track record shows an average 90-day return of +1.2%, though these backward-looking returns do not inform the timing of this scheduled transaction. The company shows solid fundamentals with revenue of $21,979,000.00, net income of $5,818,000.00, annual growth of 14.4%, and a P/E of 48.86.

CEO Susi Roger E. sells 7,500 IRMD shares for ~$631K; stock off 20% from 52-week highs; all five prior sales poorly timed.

Susi Roger E., IRMD's CEO, President, and Chairman, executed five separate sales totaling 7,500 shares in a two-day window. The stock is currently trading well below its 52-week high, down sharply over both the prior month and quarter. Despite this weakness, Susi's track record at this ticker has been consistently poor: all five of his previous sales at IRMD were followed by gains in the stock, meaning he exited too early each time. This filing repeats that pattern—adding to six prior open-market sales at this company within the measurement window. The company itself remains profitable with solid revenue growth, so the selling does not reflect fundamental distress. Without visibility into Susi's personal liquidity needs or estate planning, the repeated exits during a period of stock decline raise a question: is the CEO unwinding shares regardless of price momentum, or does he see value better realized elsewhere?

CEO Susi Roger E. sells 7,500 shares for $643K; 12th IRMD sale in 36 months, continuing an all-sell pattern with historically poor timing.

Susi Roger E., the CEO, President, and Chairman of IRADIMED, sold 7,500 shares across seven transactions in early May for a combined $643K, bringing his total open-market sales at this company to twelve over the past three years—with zero purchases during the same period. His track record on prior IRMD sales is notably poor: every one of his five prior sales at this ticker was followed by the stock rising, meaning he consistently exited too early. The current sale occurs while the company remains profitable and growing revenue in the double digits, though the stock is trading about 21% below its 52-week high and down roughly 14% over the past quarter. Roger E.'s three-year pattern of sell-only activity, combined with universally mistimed prior exits at this stock, suggests a mechanical liquidation pattern rather than tactical conviction about near-term downside—and his historical track record offers little evidence he successfully times these sales to protect value.